×
About 783 results

ALLMedicine™ Targeted Cancer Therapy Center

Research & Reviews  285 results

ATEMPT 2.0: Adjuvant T-DM1 vs TH
https://clinicaltrials.gov/ct2/show/NCT04893109

Jun 22nd, 2022 - This is a randomized phase II adjuvant study for women and men with Stage I HER2-positive invasive breast cancer. Participants will be randomized into one of two treatment arms in this study and receive: Arm 1: trastuzumab-emtansine (T-DM1, Kadcyl...

Current Update on Nanotechnology-Based Approaches in Ovarian Cancer Therapy.
https://doi.org/10.1007/s43032-022-00968-1 10.1093/annonc/mdj978 10.1080/14737140.2016.1192471 10.2147/OTT.S105587 10.1056/NEJMoa1304369 10.2217/17435889.1.2.229 10.1002/pat.3991 10.1016/S0065-2571(00)00013-3 10.1016/S0169-409X(97)00095-1 10.1073/pnas.0504274102 10.1038/nm0902-918 10.1016/S1369-7021(05)71034-8 10.1016/j.actbio.2012.04.029 10.1002/1520-6017(200011)89:11<1452::AID-JPS8>3.0.CO;2-P 10.1007/s11051-013-1897-6 10.3390/antiox9020133 10.1039/C4PY00601A 10.1039/c2cs35103j 10.1007/s11095-009-9992-1 10.1016/j.nano.2014.09.006 10.1016/0014-5793(92)80947-F 10.1016/j.jconrel.2018.10.021 10.1186/s12885-016-2870-4 10.1016/j.colsurfb.2018.06.055 10.1158/1535-7163.MCT-15-0986 10.1039/C8TB03123A 10.1016/j.biomaterials.2014.01.035 10.1007/s12291-016-0596-3 10.7150/thno.23050 10.1021/acs.chemmater.6b01280 10.1016/j.ijpharm.2019.118751 10.1021/acsami.5b09340 10.1186/s12906-018-2127-7 10.1111/jphp.12675 10.1016/j.colsurfb.2017.06.025 10.1080/1061186X.2016.1236113 10.1186/1757-2215-3-11 10.1016/j.ejps.2013.08.036 10.1016/j.colsurfb.2019.03.037 10.1039/C6RA17609G 10.2147/IJN.S144161 10.2174/1871520616666160624091519 10.3390/ijms19030710 10.1038/sj.bjc.6604930 10.1146/annurev.biochem.76.052705.162114 10.1039/C7NR04473A 10.1186/s13046-016-0320-4 10.1158/0008-5472.CAN-16-1115 10.1016/j.biopha.2018.05.077 10.1371/journal.pone.0096718 10.1016/j.canlet.2013.11.004 10.1158/0008-5472.CAN-11-3160 10.1021/acsami.9b07980 10.1016/j.canlet.2019.07.002 10.1021/acsami.7b19183 10.2217/nnm-2018-0205 10.1166/jnn.2020.17301 10.2217/nnm.15.27 10.1158/1535-7163.MCT-13-0930 10.1038/sj.onc.1207721 10.1039/C5TB01238D 10.1021/mp500259e 10.1021/acsbiomaterials.0c00330 10.1016/j.ejps.2013.10.011 10.1016/j.nano.2016.11.010 10.1021/acs.biomac.5b01189 10.1016/j.biomaterials.2018.08.001 10.1021/nn304347g 10.1088/1361-6528/ab1857 10.1021/acsnano.6b06796 10.1186/s13048-016-0230-2 10.1038/nmeth818 10.1016/j.colsurfb.2018.03.016 10.3390/cancers11111760 10.1039/C6TB01988A 10.1039/C6PP00340K 10.1016/j.jphotobiol.2018.07.013 10.1615/CritRevOncog.2014011455 10.3390/pharmaceutics11030110 10.1007/s00280-012-2042-4
Reproductive Sciences (Thousand Oaks, Calif.); Bhardwaj BK, Thankachan S et. al.

May 19th, 2022 - Ovarian cancer is one of the leading causes of cancer-related deaths among women. The drawbacks of conventional therapeutic strategies encourage researchers to look for alternative strategies, including nanotechnology. Nanotechnology is one of the...

Deficiency of the splicing factor RBM10 limits EGFR inhibitor response in EGFR mutant l...
https://doi.org/10.1172/JCI145099
The Journal of Clinical Investigation; Nanjo S, Wu W et. al.

May 18th, 2022 - Molecularly targeted cancer therapy has improved outcomes for cancer patients with targetable oncoproteins, such as mutant epidermal growth factor receptor (EGFR) in lung cancer. Yet, long-term patient survival remains limited because treatment re...

The prognostic significance of bromodomain protein 4 expression in solid tumor patients...
https://doi.org/10.1016/j.prp.2022.153918
Pathology, Research and Practice; Wang Y, Wu Y et. al.

May 14th, 2022 - Cancer is a leading cause of death worldwide. At present, several inhibitors of bromodomain protein 4 have shown promising anti-tumor responses in clinical trials. Numerous studies have reported the value of bromodomain protein 4 expression in pre...

Prophylaxis of Diarrhea in Adult Cancer Patients Receiving Targeted Cancer Therapy
https://clinicaltrials.gov/ct2/show/NCT04538625

May 4th, 2022 - A randomized, placebo controlled, double blind study to evaluate the safety and efficacy of crofelemer in providing prophylaxis of diarrhea in adult patients with solid tumors receiving targeted cancer therapy containing regimens. Diarrhea grading...

see more →

Clinicaltrials.gov  7 results

ATEMPT 2.0: Adjuvant T-DM1 vs TH
https://clinicaltrials.gov/ct2/show/NCT04893109

Jun 22nd, 2022 - This is a randomized phase II adjuvant study for women and men with Stage I HER2-positive invasive breast cancer. Participants will be randomized into one of two treatment arms in this study and receive: Arm 1: trastuzumab-emtansine (T-DM1, Kadcyl...

Prophylaxis of Diarrhea in Adult Cancer Patients Receiving Targeted Cancer Therapy
https://clinicaltrials.gov/ct2/show/NCT04538625

May 4th, 2022 - A randomized, placebo controlled, double blind study to evaluate the safety and efficacy of crofelemer in providing prophylaxis of diarrhea in adult patients with solid tumors receiving targeted cancer therapy containing regimens. Diarrhea grading...

ATOP TRIAL: T-DM1 in HER2 Positive Breast Cancer
https://clinicaltrials.gov/ct2/show/NCT03587740

Jan 11th, 2022 - This research study is a Phase II clinical trial. Phase II clinical trials test the safety and effectiveness of an investigational drug to learn whether the drug works in treating a specific disease. "Investigational" means that the drug is being ...

ATOP TRIAL: T-DM1 in HER2 Positive Breast Cancer
https://clinicaltrials.gov/ct2/show/NCT02414646

Jan 18th, 2020 - This research study is a Phase II clinical trial. Phase II clinical trials test the safety and effectiveness of an investigational drug to learn whether the drug works in treating a specific disease. "Investigational" means that the drug is being ...

OSI-774 (Erlotinib, Tarceva) in Elderly Patients
https://clinicaltrials.gov/ct2/show/NCT00200395

Dec 30th, 2019 - In recent years, it has been shown that the degree of improvement achievable with chemotherapy has plateaued with the use of chemotherapy doublets. The presence of co-morbid conditions and poor performance status may preclude the use of chemothera...

see more →

News  21 results

Genomic Testing Challenges Persist
https://www.onclive.com/view/genomic-testing-challenges-persist

May 5th, 2022 - Although molecular biomarkers are becoming increasingly relevant in cancer care, community oncologists confront a plethora of challenges in translating research findings into practice. Structural changes in payment systems and decision-support too...

First FDA Recognition for Tumor Marker Database 
https://www.medscape.com/viewarticle/963334

Nov 19th, 2021 - In the 20 years since the first targeted cancer therapy was approved, more than 100 such products are now on the market or in development. These targeted drugs offer a different approach to the carpet bombing of chemotherapy — they are precise mis...

Review eyes nail unit toxicities secondary to targeted cancer therapy
https://www.mdedge.com/dermatology/article/244613/hair-nails/review-eyes-nail-unit-toxicities-secondary-targeted-cancer
Doug Brunk

Aug 24th, 2021 - Paronychia and periungual pyogenic granulomas are the most common nail unit toxicities related to targeted cancer therapies and immunotherapies, while damage to other nail unit anatomic areas can be wide-ranging. Those are key findings from an evi.

Review Eyes Nail Unit Toxicities Secondary to Targeted Cancer Therapy
https://www.medscape.com/viewarticle/957155

Aug 24th, 2021 - Paronychia and periungual pyogenic granulomas are the most common nail unit toxicities related to targeted cancer therapies and immunotherapies, while damage to other nail unit anatomic areas can be wide-ranging. Those are key findings from an evi...

Is It Time for Universal Genetic Testing in Colorectal Cancer?
https://www.medscape.com/viewarticle/950031

Apr 27th, 2021 - Universal multigene panel testing of colorectal cancer patients can detect heritable mutations that would not have been discovered with guideline-based testing, according to new research. A prospective study of universal genetic testing suggested ...

see more →